COBAS? AMPLIPREP/COBAS? TAQMAN? HBV TEST, V2.0 CE-IVD 04894570190

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a 01,05 report with the FDA on 2011-08-24 for COBAS? AMPLIPREP/COBAS? TAQMAN? HBV TEST, V2.0 CE-IVD 04894570190 manufactured by Roche Molecular Systems.

Event Text Entries

[2264691] A customer from (b)(6) filed a complaint alleging that discrepant hbv results were generated for two samples with the cobas ampliprep/cobas taqman (cap/ctm) hbv v2. 0 test when compared to the versant bdna test. The results with one sample were (b)(6) with cap/ctm hbv v2. 0 and (b)(6) with versant bdna. It is planned to obtain sequencing information for the sample. The other sample is addressed in mdr 2243471-2011-00077.
Patient Sequence No: 1, Text Type: D, B5


[9261394] The issue is under investigation. No conclusions can be drawn at this time. (b)(4).
Patient Sequence No: 1, Text Type: N, H10


[9290192] (b)(4): method: analysis of labeling and (review of design history data and analysis of raw data from the customer site). Result: device performed according to specifications. Conclusion: no failure detected and product performed within specification. No product or batch non-conformance was identified. Analysis of the raw data does not show any indication of an issue with the cobas ampliprep/ cobas taqman system (i. E. Curve anomalies, pipetting problems, etc. ). Upon investigation there was no trend found in the field. Qc release data for n11158 was reviewed and the issue of discrepant results has not been observed. There have not been any manufacturing non-conformance reports for batch n11158. The package insert for this test includes a correlation study between the cap-ctm hbv test and the versant hbv dna test. The study includes one sample with similarly discrepant results (log 2 for cap-ctm and log 5 for versant). Review of the design history file for this study shows that the study sample was sequenced and had no mismatches that would affect the cap-ctm test. The study sample also correlated well between cap-ctm, abbott, cobas amplicor and high pure tests. The study sample was retested with cap-ctm and the same results were confirmed. There are no additional conclusions made in the study regarding this discrepancy, however, it could be that the versant tests over quantifies this sample. No sample material was available from the customer for investigative testing to confirm the presence of any sequence mismatches or to further evaluation this issue. (b)(4).
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number2243471-2011-00076
MDR Report Key2222041
Report Source01,05
Date Received2011-08-24
Date of Report2011-07-26
Date of Event2011-07-13
Date Mfgr Received2011-09-01
Date Added to Maude2012-02-13
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional0
Initial Report to FDA0
Report to FDA0
Event Location0
Manufacturer ContactVINCENT STAGNITTO
Manufacturer Street1080 US HWY 202
Manufacturer CityBRANCHBURG NJ 088763733
Manufacturer CountryUS
Manufacturer Postal088763733
Manufacturer Phone9082537569
Manufacturer G1ROCHE MOLECULAR SYSTEMS
Manufacturer Street1080 US HWY 202
Manufacturer CityBRANCHBURG NJ 08876373
Manufacturer CountryUS
Manufacturer Postal Code08876 3733
Single Use0
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameCOBAS? AMPLIPREP/COBAS? TAQMAN? HBV TEST, V2.0 CE-IVD
Generic NameHEPATITIS VIRAL B DNA DETECTION
Product CodeMKT
Date Received2011-08-24
Catalog Number04894570190
Lot NumberN18322
Device Expiration Date2012-03-30
Device AgeDA
Device Eval'ed by MfgrY
Device Sequence No1
Device Event Key0
ManufacturerROCHE MOLECULAR SYSTEMS
Manufacturer Address1080 US HWY 202 BRANCHBURG NJ 08876373 US 08876 3733


Patients

Patient NumberTreatmentOutcomeDate
10 2011-08-24

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.